OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AML

March 10th 2022

Geoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.

Inside the Clinic: JTCC Experts Highlight Optimal Strategies for CAR T-Cell–Related AEs

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Dr. Hurvitz on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases

March 9th 2022

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

Dr. Tolaney on Pivotal Trials in HER2+ Breast Cancer

March 9th 2022

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

March 9th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Dr. Ramnaraign on Sequencing IO and TKI Combinations in Metastatic RCC

March 8th 2022

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL

March 8th 2022

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 8th 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Larocca on What to Know when Diagnosing Difficult-to-Treat Patients in Multiple Myeloma

March 8th 2022

Alessandra Larocca, MD, PhD, discusses what to know when diagnosing difficult-to-treat patients with multiple myeloma.

Inside the Clinic: JTCC Experts Highlight Key Takeaways from ASH 2021

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

Inside the Clinic: JTCC Experts Highlight Pivotal Ongoing Trials in Multiple Myeloma

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

Dr. Jeyarajah on SIR-Spheres® Y-90 Resin Microspheres as Maintenance in CRC With Liver Metastases

March 7th 2022

Rohan Jeyarajah, MD, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer with liver metastases.

Dr. Borgen on the Immuno-Oncology Clinical Trials in Breast Cancer

March 4th 2022

Patrick Borgen, MD, discusses the evolution of immuno-oncology clinical trials in breast cancer.

Dr. Tripathy on the Emergence of Genomics Research in Breast Cancer

March 4th 2022

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

Dr. Hurvitz on Utilizing CDK4/6 Inhibitors in HR+ Breast Cancer

March 4th 2022

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.

Dr. Tolaney on Potential of Trastuzumab Deruxtecan to Shift to First Line in HER2+ Breast Cancer

March 4th 2022

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

Dr. Jagannath on the FDA Approval of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

March 3rd 2022

Sundar Jagannath, MBBS, discusses the FDA approval of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Westin on the Utilization of CAR T-Cell Therapy in LBCL

March 2nd 2022

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Dr. Hong on Objectives of the CodeBreaK 101 Trial in CRC

March 2nd 2022

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.